Pacritinib联合低剂量地西他滨治疗中高危骨髓纤维化或MPN/MDS
该数据集来自clinicaltrials.gov,聚焦于Pacritinib联合低剂量地西他滨治疗中高危骨髓纤维化或骨髓增殖性肿瘤/骨髓增生异常综合征的临床研究

基本信息
资源简介
Pacritinib联合低剂量地西他滨治疗中高危骨髓纤维化或MPN/MDS
该数据集来自clinicaltrials.gov,聚焦于Pacritinib联合低剂量地西他滨治疗中高危骨髓纤维化或骨髓增殖性肿瘤/骨髓增生异常综合征的临床研究。覆盖慢性粒单核细胞白血病、幼年型粒单核细胞白血病、非典型慢性髓性白血病、骨髓增殖性肿瘤、骨髓增生异常综合征及骨髓纤维化等疾病。数据可用于肿瘤/白血病领域的临床特征分析与治疗反应分类研究(来源 clinicaltrials.gov)。
【数据内容】
源站描述(机器翻译,仅供参考):条件:慢性粒单核细胞白血病、幼年型粒单核细胞白血病、非典型慢性髓性白血病、骨髓增殖性肿瘤、骨髓增生异常综合征、骨髓纤维化。在第一个28天周期,所有患者将接受单药Pacritinib 200 mg每日两次治疗。研究者选择该起始剂量是基于先前三项Pacritinib单药I期研究,这些研究显示最大耐受剂量(MTD)为500 mg,随后推荐400 mg每日剂量用于II期研究。最近,在2015年美国临床肿瘤学会(ASCO)年会上报告了比较Pacritinib与最佳可用疗法(BAT)治疗MF患者的III期PERSIST-1试验结果。发现Pacritinib在治疗24周时降低脾脏体积方面显著比BAT更有效,并改善
【主题与分类】
主题标签:Chronic Myelomonocytic Leukemia、Juvenile Myelomonocytic Leukemia、Atypical Chronic Myeloid Leukemia、Myeloproliferative Neoplasm、Myelodysplastic Syndromes、Myelofibrosis。本站分类:肿瘤/白血病。
【获取与许可】
源站页面:https://clinicaltrials.gov/study/NCT02564536
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取
源站:https://clinicaltrials.gov/study/NCT02564536
标准获取流程:
- 访问源站链接,注册/登录账号;
- 进入数据集详情页,按页面指引申请权限或直接下载;
- 部分平台提供 SDK,例如:
- OpenDataLab:
pip install openxlab后openxlab.dataset.get(...) - ModelScope:
pip install modelscope后modelscope download - 天池: 登录后页面提供直链下载
以源站「数据下载/使用文档」页面为准。
- OpenDataLab:
数据说明
Conditions: Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes, Myelofibrosis. For the first 28 day cycle, all patients will be treated with single agent pacritinib at 200 mg twice daily. The investigators chose this starting dose based on the previous three phase I studies of pacritinib as a single agent which showed that the maximum tolerated dose (MTD) to be 500 mg, and subsequently, the dose of 400 mg daily was recommended for the phase II studies. Recently, the results of the phase III PERSIST-1 trial comparing pacritinib to best available therapy (BAT) in patients with MF was reported at the 2015 American Society of Clinical Oncology (ASCO) annual meeting. Pacritinib was found to be significantly more effective than BAT at reducing spleen volume at 24 weeks of therapy and improving constitutional symptoms. Low dose decitabine has demonstrated depletion of DNMT1 in normal hematopoietic stem cells (HSC) without cytotoxicity and subcutaneous (SC) instead of intravenous (IV) administration may avoid high peak levels that can cause apoptosis. Furthermore, the low toxicity associated with low dose decitabine would allow for more frequent (1 to 3 times weekly) administration of the drug which would catch more cells in S-phase via greater exposure time. Based on these findings, a starting dose of decitabine 5 mg/m2 SC twice weekly should be well tolerated and effective in patients with MF and MPN/MDS syndromes when combined with pacritinib 400 mg daily.
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




